Additionally, FGF2/FGFR signaling changes are prevalent in various tumor types, with FGF2 being overexpressed in advanced malignant tumors, FGFR2 inhibitors playing a crucial role in tumor growth and progression, and overcoming anticancer drug resistance through novel extracellular inhibitors [21]. This evidence concerns the gene FGFR2 and neoplasm.